Shenzhen Mindray Bio-Medical Electronics Co.,Ltd. (300760) announced that the company held its 14th meeting of the eighth board of directors on October 14, 2025, during which it approved the appointment of Ernst & Young as the special audit institution for the issuance of overseas-listed foreign shares (H-shares) and listing on the main board of the Hong Kong Stock Exchange.
In the first half of 2025, Shenzhen Mindray Bio-Medical Electronics achieved revenue of 16.743 billion yuan and net profit attributable to shareholders of 5.069 billion yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments